Evidence map›Paper›PMID 38835498›Full record

ArticleOpen forum infectious diseases2024

Clinical Features and Genomic Epidemiology of Bloodstream Infections due to Enterococcal Species Other Than

Dierdre B Axell-House, Patrycja A Ashley, Stephanie L Egge, Truc T Tran, Claudia Pedroza, Meng Zhang, An Q Dinh, Shelby R Simar, Pranoti V Sahasrabhojane, William R Miller and 3 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Unlocking the Potential ofMicroorganisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dierdre B Axell-HouseDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Patrycja A AshleyDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Stephanie L EggeDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Truc T TranCenter for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
Claudia PedrozaCenter for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Meng ZhangCenter for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
An Q DinhCenter for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
Shelby R SimarCenter for Infectious Diseases, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Pranoti V SahasrabhojaneDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
William R MillerDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Samuel A ShelburneDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9721-263X
Blake M HansonCenter for Infectious Diseases, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-2949-7818
Cesar A AriasDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.

Funding

Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2025
$12.0M
VENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9M
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
Molecular Basis of Infectious Diseases Training GrantT32AI055449 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LORENZ, MICHAEL C · 2005 to 2025
$2.6M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
Role of YxdJK and DAK in the Enterococcal Envelope Stress ResponseK08AI135093 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILLER, WILLIAM R · 2018 to 2022
$929k
Mobile Genetic Elements and Clinical Outcomes in Staphylococcus aureus BacteremiaK01AI148593 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HANSON, BLAKE M · 2020 to 2023
$519k
Emergence of TonB-dependent receptor mediated cefiderocol resistance among multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates.R21AI175821 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI MILLER, WILLIAM R · 2023 to 2024
$467k
NIAID NIH HHS K01 AI148593NIAID NIH HHS K08 AI135093NIAID NIH HHS K24 AI121296NIAID NIH HHS L30 AI154520NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R21 AI175821NIAID NIH HHS T32 AI055449NIAID NIH HHS T32 AI141349
6 · The paper itself

Abstract

Background: Non- Methods: We conducted a retrospective review of all patients (n = 70) with NFF bacteremia from 2016 to 2022 at a major cancer center. The main outcomes assessed were 30-day mortality, microbiological failure (positive blood cultures for ≥4 days), and recurrence of bacteremia (positive blood culture <14 days after clearance). Whole-genome sequencing was performed on all available NFF (n = 65). Results: Patients with hematological malignancies made up 56% of the cohort (77% had leukemia). The majority of solid malignancies (87%) were gastrointestinal in origin. The majority of infections (83%) originated from an intra-abdominal source. The most common NFF species were Conclusions: NFF bacteremia is caused by a heterogeneous population of isolates and is associated with significant mortality. Hematological malignancy is an important risk factor for infection with NFF resistant to multiple antibiotics.

Indexed as

bloodstream infectioncancerE. gallinarumenterococcivanC

Identifiers

PMID38835498
PMCPMC11148474

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.